Total Payments
$928,176
2024 Payments
$28,739
Companies
60
Transactions
2,088
Medicare Patients
5,458
Medicare Billing
$884,876
Payment Breakdown by Category
Other$804,635 (86.7%)
Travel$56,789 (6.1%)
Food & Beverage$48,541 (5.2%)
Consulting$17,955 (1.9%)
Education$196.89 (0.0%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $804,135 | 635 | 86.6% |
| Travel and Lodging | $56,789 | 224 | 6.1% |
| Food and Beverage | $48,541 | 1,206 | 5.2% |
| Consulting Fee | $17,955 | 7 | 1.9% |
| Honoraria | $500.00 | 1 | 0.1% |
| Education | $196.89 | 14 | 0.0% |
| Gift | $59.40 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $339,072 | 687 | $0 (2024) |
| Novo Nordisk Inc | $228,627 | 299 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $120,667 | 232 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $101,743 | 208 | $0 (2024) |
| Amarin Pharma Inc. | $63,649 | 78 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $44,881 | 67 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12,865 | 52 | $0 (2024) |
| Medtronic, Inc. | $4,580 | 32 | $0 (2024) |
| Intuity Medical Inc | $2,351 | 10 | $0 (2023) |
| ABBVIE INC. | $1,024 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,739 | 202 | Lilly USA, LLC ($18,270) |
| 2023 | $43,049 | 236 | Lilly USA, LLC ($33,237) |
| 2022 | $85,238 | 248 | Lilly USA, LLC ($40,958) |
| 2021 | $88,325 | 238 | Lilly USA, LLC ($31,423) |
| 2020 | $124,006 | 288 | Lilly USA, LLC ($59,749) |
| 2019 | $213,074 | 370 | Lilly USA, LLC ($71,562) |
| 2018 | $183,163 | 260 | Novo Nordisk Inc ($64,287) |
| 2017 | $162,584 | 246 | Lilly USA, LLC ($44,080) |
All Payment Transactions
2,088 individual payment records from CMS Open Payments — Page 1 of 84
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/29/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: Automated insulin delivery system | ||||||
| 12/19/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Endocrinology | ||||||
| 12/18/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: Durable Pump | ||||||
| 12/17/2024 | RECORDATI_RARE_DISEASES_INC. | ISTURISA (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: ENDOCRINE AGENT | ||||||
| 12/17/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Bone Health | ||||||
| 12/13/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $29.40 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: Cardio-renal | ||||||
| 12/11/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Diabetes | ||||||
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.59 | General |
| Category: DIABETES | ||||||
| 12/06/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $5.42 | General |
| Category: Endocrinology | ||||||
| 12/05/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $7.69 | General |
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Cardio-renal | ||||||
| 11/25/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $29.40 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/22/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $29.61 | General |
| Category: Endocrinology | ||||||
| 11/21/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: Obesity | ||||||
| 11/20/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: Durable Pump | ||||||
| 11/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: Cardio-renal | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.74 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/15/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $34.68 | General |
| Category: Endocrinology | ||||||
| 11/14/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 11/13/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Bone Health | ||||||
| 11/12/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/10/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 11/07/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,395 | 3,199 | $593,993 | $226,629 |
| 2022 | 11 | 1,270 | 3,124 | $543,458 | $220,001 |
| 2021 | 11 | 1,287 | 3,148 | $561,500 | $231,318 |
| 2020 | 13 | 1,506 | 2,996 | $551,402 | $206,928 |
Total Patients
5,458
Total Services
12,467
Medicare Billing
$884,876
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 738 | 1,289 | $315,863 | $120,836 | 38.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 126 | 1,055 | $155,095 | $68,598 | 44.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 80 | 80 | $29,279 | $9,270 | 31.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 64 | 65 | $18,650 | $6,905 | 37.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 39 | 42 | $14,700 | $5,972 | 40.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 82 | 185 | $18,973 | $5,016 | 26.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 205 | 393 | $25,731 | $4,240 | 16.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 63 | $11,082 | $3,996 | 36.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 11 | $3,640 | $1,500 | 41.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 16 | 16 | $980.00 | $294.90 | 30.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 685 | 1,261 | $266,071 | $117,998 | 44.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 100 | 1,101 | $163,656 | $64,960 | 39.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 65 | 69 | $25,380 | $11,052 | 43.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 82 | 82 | $31,406 | $10,636 | 33.9% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 76 | 185 | $17,205 | $5,155 | 30.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 183 | 331 | $21,846 | $3,655 | 16.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 18 | $5,760 | $2,309 | 40.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 18 | 18 | $5,720 | $2,033 | 35.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 17 | $2,601 | $962.59 | 37.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 17 | 19 | $2,318 | $779.39 | 33.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 14 | 23 | $1,495 | $460.50 | 30.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 654 | 1,196 | $255,736 | $115,591 | 45.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 133 | 1,191 | $175,995 | $71,982 | 40.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 105 | 114 | $45,743 | $18,345 | 40.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 58 | 58 | $22,214 | $7,243 | 32.6% |
About Dr. Jane Mayrin, MD
Dr. Jane Mayrin, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1467679738.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jane Mayrin, MD has received a total of $928,176 in payments from pharmaceutical and medical device companies, with $28,739 received in 2024. These payments were reported across 2,088 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($804,135).
As a Medicare-enrolled provider, Mayrin has provided services to 5,458 Medicare beneficiaries, totaling 12,467 services with total Medicare billing of $884,876. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Philadelphia, PA
- Active Since 04/19/2007
- Last Updated 04/07/2015
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1467679738
Products in Payments
- TRULICITY (Drug) $175,978
- FARXIGA (Drug) $105,990
- Ozempic (Drug) $82,205
- MOUNJARO (Drug) $71,340
- Vascepa (Drug) $63,649
- BAQSIMI (Drug) $60,705
- Tresiba (Drug) $45,003
- INVOKANA (Drug) $44,881
- RYBELSUS (Drug) $31,252
- SOLIQUA (Drug) $26,618
- Victoza (Drug) $26,001
- TOUJEO (Drug) $24,312
- Rybelsus (Drug) $21,110
- SOLIQUA 100/33 (Drug) $20,749
- SOLIQUA 100/33 (Biological) $18,795
- JARDIANCE (Drug) $16,218
- BYDUREON (Drug) $14,611
- Xultophy 100/3.6 (Drug) $12,158
- TOUJEO (Biological) $11,141
- MINIMED 630G (Device) $3,881
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Philadelphia
Dr. Serge Jabbour, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $1.7M
Endocrinology, Diabetes & Metabolism $1.7M
Mitchell Lazar, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $432,095
Endocrinology, Diabetes & Metabolism $432,095
Jeffrey Freeman, D.o, D.O
Endocrinology, Diabetes & Metabolism — Payments: $403,058
Endocrinology, Diabetes & Metabolism $403,058
Dr. Monika Shirodkar, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $59,532
Endocrinology, Diabetes & Metabolism $59,532
Mihaela Biscoveanu, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $58,973
Endocrinology, Diabetes & Metabolism $58,973
Michael Rickels, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $41,645
Endocrinology, Diabetes & Metabolism $41,645